The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic impact of XPO1 mutations in metastatic non-small cell lung cancer (NSCLC).
 
Mohammad Fahad B. Asad
No Relationships to Disclose
 
Mohammed Najeeb Al Hallak
No Relationships to Disclose
 
Ammar Sukari
Stock and Other Ownership Interests - Merck
Honoraria - Merck Serono
Consulting or Advisory Role - Genentech
Speakers' Bureau - Eisai
 
Yasmine Baca
No Relationships to Disclose
 
Joanne Xiu
Employment - Caris Life Sciences
 
Hirva Mamdani
Consulting or Advisory Role - AstraZeneca; Zentalis
Travel, Accommodations, Expenses - AstraZeneca; Caris Life Sciences; Takeda
 
DIPESH UPRETY
No Relationships to Disclose
 
Chul Kim
Consulting or Advisory Role - Janssen; Novartis
Research Funding - AstraZeneca; Bristol-Myers Squibb; Debiopharm Group; Karyopharm Therapeutics; Novartis; Regeneron; Tesaro
 
Bing Xia
Honoraria - AstraZeneca
 
Stephen V. Liu
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; Blueprint Medicines; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; G1 Therapeutics; Genentech; Guardant Health; Inivata; Janssen Oncology; Jazz Pharmaceuticals; Lilly; MSD Oncology; Pfizer; PharmaMar; Regeneron; Takeda
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Debiopharm Group (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Lilly (Inst); Lycera (Inst); Merck (Inst); Merus (Inst); Molecular Partners (Inst); Pfizer (Inst); Rain Therapeutics (Inst); RAPT Therapeutics (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Roche/Genentech
 
Jorge J. Nieva
Stock and Other Ownership Interests - Cansera; Epic Sciences; Indee P/L; Quantgene
Consulting or Advisory Role - AstraZeneca; Fujirebio Diagnostics; Naveris
Research Funding - Merck
Patents, Royalties, Other Intellectual Property - Patent Pending - movement and unexpected healthcare encounters
 
Gilberto Lopes
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - Abbvie (Inst); adaptimmune (Inst); AstraZeneca; AstraZeneca (Inst); Bavarian Nordic (Inst); Blueprint Medicines (Inst); BMS (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lucence; Merck Sharp & Dohme (Inst); NOVARTIS (Inst); Pfizer (Inst); Rgenix (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; E.R. Squibb Sons, LLC; Janssen; Pfizer
 
Hossein Borghaei
Stock and Other Ownership Interests - Rgenix; Sonnet
Honoraria - Amgen; Axiom Biotechnologies; Bristol-Myers Squibb; Celgene; Pfizer
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb; Cantargia AB; Celgene; EMD Serono; Genentech; Genmab; HUYA Bioscience International; Lilly; Merck; Novartis; Pfizer; PharmaMar; Regeneron; Rgenix; Sonnet; Takeda; Trovagene
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly; Merck; Novartis
Other Relationship - Incyte; Takeda; University of Pennsylvania
 
Michael J. Demeure
Consulting or Advisory Role - Avant Diagnostics; Bayer; Loxo/Lilly; Orphagen Pharmaceuticals; TD2
(OPTIONAL) Uncompensated Relationships - transmed7
 
Luis E. Raez
Research Funding - Amgen (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Heat Biologics (Inst); Loxo (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Syndax (Inst)
 
Patrick C. Ma
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences
Speakers' Bureau - AstraZeneca; Merck
Research Funding - Abbvie (Inst); Apollomics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EpicentRx (Inst); Loxo (Inst); Merck (Inst); Tesaro (Inst)
 
Sonam Puri
Consulting or Advisory Role - AstraZeneca (Inst); G1 Therapeutics (Inst)
 
Wolfgang Michael Korn
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Consulting or Advisory Role - Merck Sharp & Dohme
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Asfar S. Azmi
Consulting or Advisory Role - Gerson Lehrman Group; Guidepoint Inc
Speakers' Bureau - Karyopharm Therapeutics
Research Funding - Eisai
 
Misako Nagasaka
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; Daiichi Sankyo; EMD Serono; Novartis; Takeda
Speakers' Bureau - Blueprint Medicines
Research Funding - Tempus
Travel, Accommodations, Expenses - Anheart Therapeutics